Australia and New Zealand In Vitro Diagnostics Market Size: By Technology: Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, Hematology, Others; By Product and Services: Instruments, Reagents and Kits, Services, Data Management Software; By Applications; By End User; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Australia and New Zealand In Vitro Diagnostics Market Overview 
    3.1    Australia and New Zealand In Vitro Diagnostics Market Historical Value (2017-2023) 
    3.2    Australia and New Zealand In Vitro Diagnostics Market Forecast Value (2024-2032)
4    Australia and New Zealand In Vitro Diagnostics Market Dynamics
    4.1    Market Drivers and Constraints
    4.2    SWOT Analysis
    4.3    Porter’s Five Forces Model 
    4.4    Key Demand Indicators
    4.5    Key Price Indicators
    4.6    Industry Events, Initiatives, and Trends 
    4.7    Value Chain Analysis
5    Australia and New Zealand In Vitro Diagnostics Market Segmentation 
5.1    Australia and New Zealand In Vitro Diagnostics Market by Technology
    5.1.1    Market Overview                                     
        5.1.2    Clinical Chemistry
        5.1.3    Molecular Diagnostics
        5.1.4    Immuno Diagnostics
        5.1.5    Hematology
        5.1.6    Others
    5.2    Australia and New Zealand In Vitro Diagnostics Market by Product and Services
        5.2.1    Market Overview
        5.2.2    Instruments
        5.2.3    Reagents and Kits
        5.2.4    Services
        5.2.5    Data Management Software
    5.3    Australia and New Zealand In Vitro Diagnostics Market by Applications
        5.3.1    Market Overview
        5.3.2    Infectious Disease
        5.3.3    Diabetes
        5.3.4    Cancer/Oncology
        5.3.5    Cardiology
        5.3.6    Autoimmune Disease
        5.3.7    Other Applications 
    5.4    Australia and New Zealand In Vitro Diagnostics Market by End User
        5.4.1    Market Overview
        5.4.2    Diagnostic Laboratories
        5.4.3    Hospitals and Clinics
        5.4.4    Academic Institutes
        5.4.5    Point-of-Care Testing centers
        5.4.6    Others
    5.5    Australia and New Zealand In Vitro Diagnostics Market by Country
        5.5.1    Market Overview
        5.5.2    Australia
        5.5.3    New Zealand 
6    Patent Analysis
    6.1    Analysis by Type of Patent
    6.2    Analysis by Publication year
    6.3    Analysis by Issuing Authority
    6.4    Analysis by Patent Age
    6.5    Analysis by CPC Analysis
    6.6    Analysis by Patent Valuation 
    6.7    Analysis by Key Players
7    Grants Analysis
    7.1    Analysis by year
    7.2    Analysis by Amount Awarded
    7.3    Analysis by Issuing Authority
    7.4    Analysis by Grant Application
    7.5    Analysis by Funding Institute
    7.6    Analysis by NIH Departments
    7.7    Analysis by Recipient Organization
8    Funding Analysis
    8.1    Analysis by Funding Instances
    8.2    Analysis by Type of Funding
    8.3    Analysis by Funding Amount
    8.4    Analysis by Leading Players
    8.5    Analysis by Leading Investors
    8.6    Analysis by Geography
9    Partnership and Collaborations Analysis
    9.1    Analysis by Partnership Instances
    9.2    Analysis by Type of Partnership
    9.3    Analysis by Leading Players
    9.4    Analysis by Geography
10    Regulatory Framework
    10.1    Regulatory Overview
11    Supplier Landscape
    11.1    BioMerieux SA
        11.1.1    Financial Analysis
        11.1.2    Product Portfolio
        11.1.3    Demographic Reach and Achievements
        11.1.4    Mergers and Acquisitions
        11.1.5    Certifications
    11.2    F. Hoffmann-La Roche Ltd
        11.2.1    Financial Analysis
        11.2.2    Product Portfolio
        11.2.3    Demographic Reach and Achievements
        11.2.4    Mergers and Acquisitions
        11.2.5    Certifications
    11.3    Becton, Dickinson and Company
        11.3.1    Financial Analysis
        11.3.2    Product Portfolio
        11.3.3    Demographic Reach and Achievements
        11.3.4    Mergers and Acquisitions
        11.3.5    Certifications
    11.4    Bio-Rad Laboratories Inc.
        11.4.1    Financial Analysis
        11.4.2    Financial Portfolio
        11.4.3    Demographic Reach and Achievements
        11.4.4    Mergers and Acquisitions
        11.4.5    Certifications
    11.5    Abbott Laboratories, Inc.
        11.5.1    Financial Analysis
        11.5.2    Product Portfolio
        11.5.3    Demographic Reach and Achievements
        11.5.4    Mergers and Acquisitions
        11.5.5    Certifications
    11.6    Siemens AG
        11.6.1    Financial Analysis
        11.6.2    Product Portfolio
        11.6.3    Demographic Reach and Achievements
        11.6.4    Mergers and Acquisitions
        11.6.5    Certifications
    11.7    Thermo Fisher Scientific, Inc.
        11.7.1    Financial Analysis
        11.7.2    Product Portfolio
        11.7.3    Demographic Reach and Achievements
        11.7.4    Mergers and Acquisitions
        11.7.5    Certifications
    11.8    QIAGEN N.V.
        11.8.1    Financial Analysis
        11.8.2    Product Portfolio
        11.8.3    Demographic Reach and Achievements
        11.8.4    Mergers and Acquisitions
        11.8.5    Certifications
    11.9    Roche Diagnostics
        11.9.1    Financial Analysis
        11.9.2    Product Portfolio
        11.9.3    Demographic Reach and Achievements
        11.9.4    Mergers and Acquisitions
        11.9.5    Certifications
    11.10    Danaher Corporation
        11.10.1    Financial Analysis
        11.10.2    Product Portfolio
        11.10.3    Demographic Reach and Achievements
        11.10.4    Mergers and Acquisitions
        11.10.5    Certifications
    11.11    Agilent Technologies, Inc
        11.11.1    Financial Analysis
        11.11.2    Product Portfolio
        11.11.3    Demographic Reach and Achievements
        11.11.4    Mergers and Acquisitions
        11.11.5    Certifications
    11.12    Quidel Corporation
        11.12.1    Financial Analysis
        11.12.2    Product Portfolio
        11.12.3    Demographic Reach and Achievements
        11.12.4    Mergers and Acquisitions
        11.12.5    Certifications
    11.13    Diasorin S.P.A
        11.13.1    Financial Analysis
        11.13.2    Product Portfolio
        11.13.3    Demographic Reach and Achievements
        11.13.4    Mergers and Acquisitions
        11.13.5    Certifications
    11.14    Illumina, Inc.
        11.14.1    Financial Analysis
        11.14.2    Product Portfolio
        11.14.3    Demographic Reach and Achievements
        11.14.4    Mergers and Acquisitions
        11.14.5    Certifications
    11.15    Hologic, Inc
        11.15.1    Financial Analysis
        11.15.2    Product Portfolio
        11.15.3    Demographic Reach and Achievements
        11.15.4    Mergers and Acquisitions
        11.15.5    Certifications
12    Australia and New Zealand In Vitro Diagnostics Market - Distribution Model (Additional Insight)
    12.1    Overview 
    12.2    Potential Distributors 
    12.3    Key Parameters for Distribution Partner Assessment 
13    Key Opinion Leaders (KOL) Insights (Additional Insight)
14    Company Competitiveness Analysis (Additional Insight)
    14.1    Very Small Companies
    14.2    Small Companies
    14.3    Mid-Sized Companies
    14.4    Large Companies
    14.5    Very Large Companies
15    Payment Methods (Additional Insight)
    15.1    Government Funded
    15.2    Private Insurance
    15.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.